Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127077) titled 'A Prospective Clinical Study Evaluating the Efficacy and Safety of Zorifertinib in Combination with Sacituzumab Tirumotecan in Patients with EGFR-mutated NSCLC and Brain Metastases after First-line Resistance to Third-generation EGFR-TKIs' on June 24.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shanghai Pulmonary Hospital
Condition:
Non-small cell lung cancer patients with brain parenchymal metastasis (except meningeal metastasis) diagnosed by imaging after disease progression during first-line treatment with third-generation EGFR-TKIs (single agent or combination)
Recruitment ...